Long-COVID olfactory dysfunction: allele E4 of apolipoprotein E as a possible protective factor
Authors:
- Danilo Nunes OliveiraDODanilo Nunes Oliveira
- José Wagner Leonel Tavares-JúniorJTJosé Wagner Leonel Tavares-Júnior
- Werbety Lucas Queiroz FeitosaWFWerbety Lucas Queiroz Feitosa
- Letícia Chaves Vieira CunhaLCLetícia Chaves Vieira Cunha
- Carmem Meyve Pereira GomesCGCarmem Meyve Pereira Gomes
- Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
- Jean Breno Silveira da SilvaJSJean Breno Silveira da Silva
- Artur Victor Menezes SousaASArtur Victor Menezes Sousa
- Safira de Brito GasparSGSafira de Brito Gaspar
- Emmanuelle Silva Tavares SobreiraESEmmanuelle Silva Tavares Sobreira
- Laís Lacerda Brasil de OliveiraLOLaís Lacerda Brasil de Oliveira
- Raquel Carvalho MontenegroRMRaquel Carvalho Montenegro
Open Access
- 18 July 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (09) , 001-007
Abstract
Background Olfactory dysfunction (OD) represents a frequent manifestation of the coronavirus disease 2019 (COVID-19). Apolipoprotein E (APOE) is a protein that interacts with the angiotensin-converting enzyme receptor, essential for viral entry into the cell. Previous publications have suggested a possible role of APOE in COVID-19 severity. As far as we know, no publications found significant associations between this disease's severity, OD, and APOE polymorphisms (E2, E3, and E4). Objective To analyze the epidemiology of OD and its relationship with APOE polymorphisms in a cohort of Long-COVID patients. Methods We conducted a prospective cohort study with patients followed in a post-COVID neurological outpatient clinic, with OD being defined as a subjective reduction of olfactory function after infection, and persistent OD being defined when the complaint lasted more than 3 months after the COVID-19 infection resolution. This cross-sectional study is part of a large research with previously reported data focusing on the cognitive performance of our sample. Results The final sample comprised 221 patients, among whom 186 collected blood samples for APOE genotyping. The persistent OD group was younger and had a lower hospitalization rate during the acute phase of the disease (p < 0.001). Furthermore, the APOE variant E4 allele frequency was lower in this group (p = 0.035). This study evaluated OD in an outpatient population with COVID-19. In the current literature on this disease, anosmia is associated with better clinical outcomes and the E4 allele is associated with worse outcomes. Conclusion Our study provides new information to these correlations, suggesting APOE E4 as a protective factor for OD.Keywords
This publication has 28 references indexed in Scilit:
- Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adultsAlzheimer's & Dementia, 2022
- Olfactory dysfunction in COVID-19: pathology and long-term implications for brain healthTrends in Molecular Medicine, 2022
- Olfactory dysfunction in COVID-19: a marker of good prognosis?Brazilian Journal of Otorhinolaryngology, 2022
- COVID-19 associated cognitive impairment: A systematic reviewCortex, 2022
- Population differences between COVID‐19 and other postviral olfactory dysfunction: Results from a large case–control studyInternational Forum of Allergy & Rhinology, 2022
- Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?Medical Hypotheses, 2021
- Anosmia is associated with lower in-hospital mortality in COVID-19Journal of the Neurological Sciences, 2020
- Olfactory dysfunction from acute upper respiratory infections: relationship to season of onsetInternational Forum of Allergy & Rhinology, 2020
- Postviral olfactory lossOtolaryngologic Clinics of North America, 2004
- Apolipoprotein E polymorphism and Alzheimer's diseaseThe Lancet, 1993